Evidence map›Paper›PMID 26547749›Full record

ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2015

SOD mimetic activity and antiproliferative properties of a novel tetra nuclear copper (II) complex.

Sagiv Weintraub, Yoni Moskovitz, Ohad Fleker, Ariel R Levy, Aviv Meir, Sharon Ruthstein, Laurent Benisvy, Arie Gruzman

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. In vitro and in vivo anti-proliferative evaluation of bis(4'-(4-tolyl)-2,2':6',2″-terpyridine)copper(II) complex against Ehrlich ascites carcinoma tumors.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sagiv WeintraubDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel.
Yoni MoskovitzDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel.
Ohad FlekerDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel.
Ariel R LevyDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel.
Aviv MeirDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel.
Sharon RuthsteinDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel.
Laurent BenisvyDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel. benisvy@gmail.com.
Arie GruzmanDepartment of Chemistry, Bar-Ilan University, 5290002, Ramat Gan, Israel. gruzmaa@biu.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for novel anticancer therapeutic agents is an urgent and important issue in medicinal chemistry. Here, we report on the biological activity of the copper-based bioinorganic complex Cu4 (2,4-di-tert-butyl-6-(1H-imidazo- [1, 10] phenanthrolin-2-yl)phenol)4]·10 CH3CN (2), which was tested in rat L6 myotubes, mouse NSC-34 motor neurone-like cells, and HepG-2 human liver carcinoma. Upon 96 h incubation, 2 exhibited a significant cytotoxic effect on all three types of cells via activation of two cell death mechanisms (apoptosis and necrosis). Complex 2 exhibited better potency and efficacy than the canonical cytotoxic drug cisplatin. Moreover, during shorter incubations, complex 2 demonstrated a significant SOD mimetic activity, and it was more effective and more potent than the well-known SOD mimetic TEMPOL. In addition, complex 2 was able to interact with DNA and, cleave DNA in the presence of sodium ascorbate. This study shows the potential of using polynuclear redox active compounds for developing novel anticancer drugs through SOD-mimetic redox pathways.

Indexed as

Biological MimicryAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCoordination ComplexesCopperDrug StabilityElectrophoresis, Agar GelHumansIronMiceMolecular StructureRatsSuperoxide DismutaseWaterAntineoplastic AgentsCoordination ComplexesCopperIronSuperoxide DismutaseWaterAnticancer drugsApoptosisCytotoxicitySOD mimeticTetra nuclear copper (II) complex

Identifiers

PMID26547749

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.